SG11201509351UA - Novel compounds for the treatment of cancer - Google Patents

Novel compounds for the treatment of cancer

Info

Publication number
SG11201509351UA
SG11201509351UA SG11201509351UA SG11201509351UA SG11201509351UA SG 11201509351U A SG11201509351U A SG 11201509351UA SG 11201509351U A SG11201509351U A SG 11201509351UA SG 11201509351U A SG11201509351U A SG 11201509351UA SG 11201509351U A SG11201509351U A SG 11201509351UA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
novel compounds
novel
compounds
Prior art date
Application number
SG11201509351UA
Inventor
Volker Schulze
Hartmut Schirok
Dirk Kosemund
Hans Briem
Benjamin Bader
Ulf Bömer
Antje Margret Wengner
Gerhard Siemeister
Philip Lienau
Detlef Stöckigt
Ulrich Lücking
Andreas Schall
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50897594&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201509351U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201509351UA publication Critical patent/SG11201509351UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SG11201509351UA 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer SG11201509351UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13171171 2013-06-10
EP13198899 2013-12-20
PCT/EP2014/061530 WO2014198594A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201509351UA true SG11201509351UA (en) 2015-12-30

Family

ID=50897594

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509351UA SG11201509351UA (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer

Country Status (25)

Country Link
US (1) US20160207928A1 (en)
EP (1) EP3008061A1 (en)
JP (1) JP2016521737A (en)
KR (1) KR20160019426A (en)
CN (1) CN105246891A (en)
AU (1) AU2014280395A1 (en)
BR (1) BR112015030774A2 (en)
CA (1) CA2914668A1 (en)
CL (1) CL2015003584A1 (en)
CR (1) CR20150653A (en)
CU (1) CU20150175A7 (en)
DO (1) DOP2015000298A (en)
EA (1) EA201501175A1 (en)
HK (1) HK1219737A1 (en)
IL (1) IL242546A0 (en)
MX (1) MX2015017011A (en)
NI (1) NI201500175A (en)
PE (1) PE20160747A1 (en)
PH (1) PH12015502747A1 (en)
SG (1) SG11201509351UA (en)
SV (1) SV2015005126A (en)
TN (1) TN2015000542A1 (en)
TW (1) TW201529560A (en)
UY (1) UY35602A (en)
WO (1) WO2014198594A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033131T2 (en) * 2013-06-11 2017-11-28 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
BR112019016635A2 (en) 2017-02-13 2020-04-07 Bristol-Myers Squibb Company aminotriazolopyridines as kinase inhibitors
PL3704118T3 (en) 2017-10-30 2022-04-04 Bristol-Myers Squibb Company Aminoimidazopyridazines as kinase inhibitors
CN109045036B (en) * 2018-07-19 2020-10-02 中山大学 Application of [1,2,4] triazolo [4,3-B ] pyridazine derivative in preparation of antitumor drugs
CN111393405B (en) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 Fluorine-containing substituted benzothiophene compounds, and pharmaceutical composition and application thereof
SG11202107080VA (en) 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
AR123793A1 (en) 2020-10-19 2023-01-11 Bristol Myers Squibb Co TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009128520A1 (en) * 2008-04-18 2011-08-04 塩野義製薬株式会社 Heterocyclic compounds having PI3K inhibitory activity
AR071523A1 (en) * 2008-04-30 2010-06-23 Merck Serono Sa FUSIONATED BICYCLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, THE COMPOSITE TO BE USED AS A MEDICINAL PRODUCT IN THE TREATMENT AND PROFILAXIS OF DISEASES, A PHARMACEUTICAL COMPOSITION AND A SET THAT INCLUDES SEPARATE PACKAGES OF THE COMPOUND AND OF AN INGREDIENT
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
US8420052B2 (en) * 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
TWI453207B (en) * 2008-09-08 2014-09-21 Signal Pharm Llc Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
WO2011110575A1 (en) * 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
AR081960A1 (en) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa HETEROCICLICAL COMPOUNDS, ITS PREPARATION AND THERAPEUTIC APPLICATION
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2694500B1 (en) * 2011-04-06 2015-05-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
KR20140025470A (en) * 2011-04-21 2014-03-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 Triazolopyridines
WO2012160029A1 (en) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
WO2013131609A1 (en) * 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives

Also Published As

Publication number Publication date
CA2914668A1 (en) 2014-12-18
UY35602A (en) 2015-01-30
IL242546A0 (en) 2016-02-01
EP3008061A1 (en) 2016-04-20
DOP2015000298A (en) 2016-03-15
PE20160747A1 (en) 2016-08-25
US20160207928A1 (en) 2016-07-21
CU20150175A7 (en) 2016-05-30
KR20160019426A (en) 2016-02-19
TW201529560A (en) 2015-08-01
CL2015003584A1 (en) 2016-06-24
BR112015030774A2 (en) 2017-07-25
MX2015017011A (en) 2016-04-25
HK1219737A1 (en) 2017-04-13
CN105246891A (en) 2016-01-13
NI201500175A (en) 2016-01-06
CR20150653A (en) 2016-03-04
EA201501175A1 (en) 2016-10-31
WO2014198594A1 (en) 2014-12-18
AU2014280395A1 (en) 2015-12-17
TN2015000542A1 (en) 2017-04-06
SV2015005126A (en) 2017-01-30
PH12015502747A1 (en) 2016-03-14
JP2016521737A (en) 2016-07-25

Similar Documents

Publication Publication Date Title
HK1247202A1 (en) Compounds for the treatment of cancer
IL241232B (en) Compounds for treatment of cancer
EP2968348A4 (en) Compounds for treatment of cancer
HUE057061T2 (en) Combination therapy for the treatment of cancer
HK1206338A1 (en) Pyrimidine compounds for the treatment of cancer
EP2925752A4 (en) Pyrimidine compounds for the treatment of cancer
HK1219737A1 (en) Novel compounds for the treatment of cancer
PL3089749T3 (en) Combined preparations for the treatment of cancer
HK1222548A1 (en) Pharmaceutical combinations for the treatment of cancer
IL245037A0 (en) Treatment for pancreatic cancer
HK1223547A1 (en) Methods for the treatment of cancer
IL245551A0 (en) Antibodies anti matriptase for the treatment of cancer
GB201607581D0 (en) Treatment of cancer
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
HK1232118A1 (en) Treatment of cancer
EP3089984A4 (en) Novel compounds for the treatment of cancer and inflammatory diseases
PL3016948T3 (en) 2-acylaminothiazoles for the treatment of cancer
EP3007712A4 (en) Treatment of cancer
ZA201704589B (en) Compounds for the treatment of cancer
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201322346D0 (en) Combination treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer